[{"id":"ca7e4b34-6f76-4ea3-8c6b-e39973324752","acronym":"NRG-LU003","url":"https://clinicaltrials.gov/study/NCT03737994","created_at":"2023-11-21T21:15:46.432Z","updated_at":"2025-02-25T12:37:11.248Z","phase":"Phase 2","brief_title":"Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer","source_id_and_acronym":"NCT03737994 - NRG-LU003","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MET","pipe":" | ","alterations":" ALK positive • MET amplification • ALK rearrangement","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • MET amplification • ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Xalkori (crizotinib) • carboplatin • Alecensa (alectinib) • Lorbrena (lorlatinib) • Zykadia (ceritinib) • pemetrexed • Alunbrig (brigatinib) • Ensacove (ensartinib) • Pemfexy (pemetrexed)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 07/25/2019","start_date":" 07/25/2019","primary_txt":" Primary completion: 07/21/2021","primary_completion_date":" 07/21/2021","study_txt":" Completion: 12/02/2025","study_completion_date":" 12/02/2025","last_update_posted":"2025-02-24"},{"id":"bbff33d0-fbb7-447e-b61a-196b5c2984ea","acronym":"ALTA-3","url":"https://clinicaltrials.gov/study/NCT03596866","created_at":"2021-01-18T17:41:06.342Z","updated_at":"2025-02-25T14:07:13.042Z","phase":"Phase 3","brief_title":"A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer","source_id_and_acronym":"NCT03596866 - ALTA-3","lead_sponsor":"Takeda","biomarkers":" ALK","pipe":" | ","alterations":" ALK positive • ALK rearrangement","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • Alecensa (alectinib) • Alunbrig (brigatinib)"],"overall_status":"Completed","enrollment":" Enrollment 248","initiation":"Initiation: 04/19/2019","start_date":" 04/19/2019","primary_txt":" Primary completion: 02/27/2024","primary_completion_date":" 02/27/2024","study_txt":" Completion: 09/12/2024","study_completion_date":" 09/12/2024","last_update_posted":"2025-02-19"},{"id":"002e6ccc-3a81-4cfa-b237-64f0c73db083","acronym":"INTUITT-NF2","url":"https://clinicaltrials.gov/study/NCT04374305","created_at":"2021-01-18T21:07:59.980Z","updated_at":"2025-02-25T14:51:47.217Z","phase":"Phase 2","brief_title":"Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)","source_id_and_acronym":"NCT04374305 - INTUITT-NF2","lead_sponsor":"Scott R. Plotkin, MD, PhD","biomarkers":" NF2","pipe":"","alterations":" ","tags":["NF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Nerlynx (neratinib) • Alunbrig (brigatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 06/20/2020","start_date":" 06/20/2020","primary_txt":" Primary completion: 12/01/2029","primary_completion_date":" 12/01/2029","study_txt":" Completion: 12/01/2030","study_completion_date":" 12/01/2030","last_update_posted":"2024-11-18"},{"id":"7c4c2c5c-0d9e-41b0-96b2-8600aa7be62a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04318938","created_at":"2021-01-18T20:55:43.511Z","updated_at":"2025-02-25T14:51:44.818Z","phase":"Phase 2","brief_title":"Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping","source_id_and_acronym":"NCT04318938","lead_sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","biomarkers":" ALK • TP53","pipe":" | ","alterations":" TP53 mutation • ALK positive • ALK rearrangement • ALK fusion • ALK mutation","tags":["ALK • TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • ALK positive • ALK rearrangement • ALK fusion • ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Alunbrig (brigatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 118","initiation":"Initiation: 03/30/2020","start_date":" 03/30/2020","primary_txt":" Primary completion: 01/16/2026","primary_completion_date":" 01/16/2026","study_txt":" Completion: 01/16/2026","study_completion_date":" 01/16/2026","last_update_posted":"2024-10-14"},{"id":"59529bbb-f615-4981-937f-6ac29b7ec1c3","acronym":"PIKACHU","url":"https://clinicaltrials.gov/study/NCT04322890","created_at":"2021-01-18T20:56:40.742Z","updated_at":"2024-07-02T16:34:59.292Z","phase":"Phase 2","brief_title":"Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation","source_id_and_acronym":"NCT04322890 - PIKACHU","lead_sponsor":"Hunan Province Tumor Hospital","biomarkers":" EGFR • BRAF • ALK • ROS1","pipe":" | ","alterations":" EGFR mutation • ALK positive • ALK mutation • ROS1 positive • ROS1 mutation","tags":["EGFR • BRAF • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK positive • ALK mutation • ROS1 positive • ROS1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • erlotinib • gefitinib • Rozlytrek (entrectinib) • Alecensa (alectinib) • Lorbrena (lorlatinib) • Zykadia (ceritinib) • pemetrexed • Alunbrig (brigatinib) • Gavreto (pralsetinib) • Ameile (aumolertinib) • Orpathys (savolitinib) • Ivesa (firmonertinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 6000","initiation":"Initiation: 04/16/2020","start_date":" 04/16/2020","primary_txt":" Primary completion: 12/24/2026","primary_completion_date":" 12/24/2026","study_txt":" Completion: 12/24/2027","study_completion_date":" 12/24/2027","last_update_posted":"2024-06-04"},{"id":"ec03da03-d224-4590-ad5d-e4c428f4a16c","acronym":"","url":"https://clinicaltrials.gov/study/NCT04227028","created_at":"2021-01-18T20:33:34.334Z","updated_at":"2024-07-02T16:35:05.549Z","phase":"Phase 1","brief_title":"Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent NSCLC","source_id_and_acronym":"NCT04227028","lead_sponsor":"City of Hope Medical Center","biomarkers":" ALK","pipe":" | ","alterations":" ALK rearrangement","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Alunbrig (brigatinib) • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 5","initiation":"Initiation: 03/09/2020","start_date":" 03/09/2020","primary_txt":" Primary completion: 11/01/2024","primary_completion_date":" 11/01/2024","study_txt":" Completion: 11/01/2024","study_completion_date":" 11/01/2024","last_update_posted":"2024-05-07"},{"id":"0d97de6b-d695-4c10-84dc-0a074a8e73a4","acronym":"CUBIK","url":"https://clinicaltrials.gov/study/NCT04223596","created_at":"2021-01-18T20:33:19.744Z","updated_at":"2024-07-02T16:35:05.887Z","phase":"Phase 2","brief_title":"Clinical Utility of Liquid Biopsy in Brigatinib ALK+ Patients","source_id_and_acronym":"NCT04223596 - CUBIK","lead_sponsor":"Fundación GECP","biomarkers":" ALK","pipe":" | ","alterations":" ALK positive • ALK rearrangement","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Alunbrig (brigatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 05/04/2020","start_date":" 05/04/2020","primary_txt":" Primary completion: 12/30/2024","primary_completion_date":" 12/30/2024","study_txt":" Completion: 04/15/2025","study_completion_date":" 04/15/2025","last_update_posted":"2024-05-06"},{"id":"11f4940a-ed4b-4469-b066-8121d8d024f6","acronym":"IFCT-2101 MASTERPROTOCOL ALK","url":"https://clinicaltrials.gov/study/NCT05200481","created_at":"2022-01-20T14:53:45.254Z","updated_at":"2024-07-02T16:35:15.769Z","phase":"Phase 2","brief_title":"Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK)","source_id_and_acronym":"NCT05200481 - IFCT-2101 MASTERPROTOCOL ALK","lead_sponsor":"Intergroupe Francophone de Cancerologie Thoracique","biomarkers":" ALK","pipe":" | ","alterations":" ALK rearrangement","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • pemetrexed • Alunbrig (brigatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 110","initiation":"Initiation: 05/18/2022","start_date":" 05/18/2022","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 10/01/2028","study_completion_date":" 10/01/2028","last_update_posted":"2024-03-07"},{"id":"97ed2644-f64f-4967-b533-941bda7608e9","acronym":"Brilliant","url":"https://clinicaltrials.gov/study/NCT05721950","created_at":"2023-02-10T15:00:12.073Z","updated_at":"2024-07-02T16:35:16.685Z","phase":"","brief_title":"A Study to Learn About Brigatinib Treatment Information Available in Chinese Participants With Non-Small-cell Lung Cancer (NSCLC)","source_id_and_acronym":"NCT05721950 - Brilliant","lead_sponsor":"Takeda","biomarkers":" ALK","pipe":" | ","alterations":" ALK rearrangement","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Alunbrig (brigatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 01/17/2024","start_date":" 01/17/2024","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-03-04"},{"id":"14b0ab67-5750-41ae-9f57-7535c1590a2a","acronym":"GALILEO","url":"https://clinicaltrials.gov/study/NCT06234579","created_at":"2024-01-31T23:19:42.835Z","updated_at":"2024-07-02T16:35:21.449Z","phase":"","brief_title":"Longitudinal Assessment of Genomic Alterations and Clonal Evolution in ALK-positive NSCLC (Galileo Project)","source_id_and_acronym":"NCT06234579 - GALILEO","lead_sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","biomarkers":" ALK","pipe":"","alterations":" ","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Alecensa (alectinib) • Lorbrena (lorlatinib) • Alunbrig (brigatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 108","initiation":"Initiation: 07/12/2021","start_date":" 07/12/2021","primary_txt":" Primary completion: 03/31/2024","primary_completion_date":" 03/31/2024","study_txt":" Completion: 07/31/2026","study_completion_date":" 07/31/2026","last_update_posted":"2024-01-31"},{"id":"91be71c1-10de-4edc-86e1-dddd4992bb1c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05100069","created_at":"2021-10-29T13:53:07.281Z","updated_at":"2024-07-02T16:35:32.810Z","phase":"","brief_title":"Survey of Brigatinib Used To Treat People With Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT05100069","lead_sponsor":"Takeda","biomarkers":" ALK","pipe":" | ","alterations":" ALK positive • ALK fusion","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ALK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Alunbrig (brigatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 500","initiation":"Initiation: 11/01/2021","start_date":" 11/01/2021","primary_txt":" Primary completion: 05/31/2026","primary_completion_date":" 05/31/2026","study_txt":" Completion: 05/31/2026","study_completion_date":" 05/31/2026","last_update_posted":"2023-10-18"},{"id":"b04e7947-58f8-4c5d-8454-cac7b455b127","acronym":"","url":"https://clinicaltrials.gov/study/NCT04592523","created_at":"2021-01-19T20:28:45.877Z","updated_at":"2024-07-02T16:35:33.821Z","phase":"","brief_title":"A Study of Usage of Brigatinib in the Treatment of Adult Participants for Approved Indications In South Korea","source_id_and_acronym":"NCT04592523","lead_sponsor":"Takeda","biomarkers":" ALK","pipe":" | ","alterations":" ALK positive","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Alunbrig (brigatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 616","initiation":"Initiation: 09/05/2019","start_date":" 09/05/2019","primary_txt":" Primary completion: 08/26/2026","primary_completion_date":" 08/26/2026","study_txt":" Completion: 08/26/2026","study_completion_date":" 08/26/2026","last_update_posted":"2023-10-12"},{"id":"14f82f5c-e429-4d17-9a3b-88bdc7d125c9","acronym":"ROME","url":"https://clinicaltrials.gov/study/NCT04591431","created_at":"2021-01-19T20:28:32.767Z","updated_at":"2025-02-25T13:53:27.554Z","phase":"Phase 2","brief_title":"The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy","source_id_and_acronym":"NCT04591431 - ROME","lead_sponsor":"Fondazione per la Medicina Personalizzata","biomarkers":" PD-L1 • BRAF","pipe":"","alterations":" ","tags":["PD-L1 • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Tecentriq (atezolizumab) • erlotinib • Yervoy (ipilimumab) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • Rozlytrek (entrectinib) • everolimus • lapatinib • Alecensa (alectinib) • Perjeta (pertuzumab) • Iclusig (ponatinib) • Kadcyla (ado-trastuzumab emtansine) • Cotellic (cobimetinib) • Talzenna (talazoparib) • Piqray (alpelisib) • Retevmo (selpercatinib) • Alunbrig (brigatinib) • Gavreto (pralsetinib) • Pemazyre (pemigatinib) • ipatasertib (RG7440) • Tepmetko (tepotinib) • itacitinib (INCB039110)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 400","initiation":"Initiation: 10/07/2020","start_date":" 10/07/2020","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2023-10-03"},{"id":"285a38cb-f600-4ae3-81a4-24752cb92918","acronym":"ENTIRETY","url":"https://clinicaltrials.gov/study/NCT05735327","created_at":"2023-02-21T16:01:46.673Z","updated_at":"2024-07-02T16:35:38.144Z","phase":"","brief_title":"A Study of Brigatinib as Preferred First Therapy for Adults With Non-Small Cell Lung Cancer (NSCLC) ENTIRETY","source_id_and_acronym":"NCT05735327 - ENTIRETY","lead_sponsor":"Takeda","biomarkers":" ALK","pipe":" | ","alterations":" ALK positive","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Alunbrig (brigatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 05/22/2023","start_date":" 05/22/2023","primary_txt":" Primary completion: 06/01/2027","primary_completion_date":" 06/01/2027","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2023-09-04"},{"id":"d2204f9f-cb2f-42ad-8ead-6b5fd4c0fd62","acronym":"ALTA-2","url":"https://clinicaltrials.gov/study/NCT03535740","created_at":"2021-01-18T17:24:57.716Z","updated_at":"2024-07-02T16:35:38.969Z","phase":"Phase 2","brief_title":"A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib","source_id_and_acronym":"NCT03535740 - ALTA-2","lead_sponsor":"Ariad Pharmaceuticals","biomarkers":" ALK","pipe":" | ","alterations":" ALK rearrangement","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Alecensa (alectinib) • Zykadia (ceritinib) • Alunbrig (brigatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 103","initiation":"Initiation: 01/31/2019","start_date":" 01/31/2019","primary_txt":" Primary completion: 09/30/2020","primary_completion_date":" 09/30/2020","study_txt":" Completion: 06/28/2024","study_completion_date":" 06/28/2024","last_update_posted":"2023-08-25"},{"id":"24922ee2-0392-4497-8896-76120a6a5470","acronym":"","url":"https://clinicaltrials.gov/study/NCT04887519","created_at":"2021-05-14T12:52:44.973Z","updated_at":"2024-07-02T16:35:50.444Z","phase":"","brief_title":"A Study of Brigatinib to Treat Adults With Anaplastic Lymphoma Kinase (ALK) Positive Metastatic Non Small Cell Lung Cancer (NSCLC)","source_id_and_acronym":"NCT04887519","lead_sponsor":"Takeda","biomarkers":" ALK","pipe":" | ","alterations":" ALK positive","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Alunbrig (brigatinib)"],"overall_status":"Completed","enrollment":" Enrollment 39","initiation":"Initiation: 12/30/2020","start_date":" 12/30/2020","primary_txt":" Primary completion: 03/31/2023","primary_completion_date":" 03/31/2023","study_txt":" Completion: 03/31/2023","study_completion_date":" 03/31/2023","last_update_posted":"2023-04-17"},{"id":"e9474c39-1ad6-4925-9b2b-111e2d5459c7","acronym":"","url":"https://clinicaltrials.gov/study/NCT03420742","created_at":"2021-01-18T16:52:33.735Z","updated_at":"2024-07-02T16:35:56.843Z","phase":"Phase 1","brief_title":"A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate, Midazolam, in Participants With ALK-Positive or ROS1-Positive Solid Tumors","source_id_and_acronym":"NCT03420742","lead_sponsor":"Takeda","biomarkers":" ROS1","pipe":" | ","alterations":" ALK positive • ROS1 positive","tags":["ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ROS1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Alunbrig (brigatinib) • midazolam hydrochloride"],"overall_status":"Completed","enrollment":" Enrollment 24","initiation":"Initiation: 06/26/2019","start_date":" 06/26/2019","primary_txt":" Primary completion: 03/24/2020","primary_completion_date":" 03/24/2020","study_txt":" Completion: 04/29/2021","study_completion_date":" 04/29/2021","last_update_posted":"2023-01-27"},{"id":"55b6f69a-db48-4a0d-83bd-a28e484eaa9a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05361564","created_at":"2022-05-05T00:56:40.306Z","updated_at":"2024-07-02T16:36:11.021Z","phase":"Phase 2","brief_title":"A Window of Opportunity Study for Investigating Drug Tolerant Persister (DTP) to Preoperative Brigatinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harboring ALK Fusions.","source_id_and_acronym":"NCT05361564","lead_sponsor":"Yonsei University","biomarkers":" ALK","pipe":" | ","alterations":" ALK rearrangement","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Alunbrig (brigatinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 06/01/2022","start_date":" 06/01/2022","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2022-05-04"},{"id":"186e697f-05ba-4731-9903-b2fbefc7858b","acronym":"","url":"https://clinicaltrials.gov/study/NCT03868423","created_at":"2021-01-18T19:04:37.636Z","updated_at":"2024-07-02T16:36:16.937Z","phase":"Phase 2","brief_title":"Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers","source_id_and_acronym":"NCT03868423","lead_sponsor":"Sameek Roychowdhury","biomarkers":" ALK • ROS1","pipe":" | ","alterations":" ALK fusion • ALK mutation • ROS1 fusion • ROS1 mutation","tags":["ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK fusion • ALK mutation • ROS1 fusion • ROS1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Alunbrig (brigatinib)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 03/20/2019","start_date":" 03/20/2019","primary_txt":" Primary completion: 11/20/2020","primary_completion_date":" 11/20/2020","study_txt":" Completion: 12/30/2021","study_completion_date":" 12/30/2021","last_update_posted":"2022-02-18"},{"id":"0e53d651-fcdf-48da-b741-de19383b8379","acronym":"BRIGAROS","url":"https://clinicaltrials.gov/study/NCT04718012","created_at":"2021-01-22T13:53:07.850Z","updated_at":"2024-07-02T16:36:20.407Z","phase":"","brief_title":"Retrospective, Observational, Multi-center Study Evaluating the Efficacy and Tolerance of Brigatinib in the Management of Rearranged CBNPC ROS1","source_id_and_acronym":"NCT04718012 - BRIGAROS","lead_sponsor":"Centre Hospitalier Intercommunal Creteil","biomarkers":" ROS1","pipe":"","alterations":" ","tags":["ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Alunbrig (brigatinib)"],"overall_status":"Completed","enrollment":" Enrollment 22","initiation":"Initiation: 03/17/2021","start_date":" 03/17/2021","primary_txt":" Primary completion: 10/17/2021","primary_completion_date":" 10/17/2021","study_txt":" Completion: 10/17/2021","study_completion_date":" 10/17/2021","last_update_posted":"2021-11-22"},{"id":"1cc6238c-be4c-4420-a4bd-d8d1becabcc9","acronym":"ALTA-1L","url":"https://clinicaltrials.gov/study/NCT02737501","created_at":"2021-01-17T17:10:12.223Z","updated_at":"2024-07-02T16:36:26.045Z","phase":"Phase 3","brief_title":"ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants","source_id_and_acronym":"NCT02737501 - ALTA-1L","lead_sponsor":"Ariad Pharmaceuticals","biomarkers":" ALK","pipe":" | ","alterations":" ALK rearrangement","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • Alunbrig (brigatinib)"],"overall_status":"Completed","enrollment":" Enrollment 275","initiation":"Initiation: 05/26/2016","start_date":" 05/26/2016","primary_txt":" Primary completion: 07/28/2020","primary_completion_date":" 07/28/2020","study_txt":" Completion: 01/29/2021","study_completion_date":" 01/29/2021","last_update_posted":"2021-08-20"},{"id":"18228bfe-0dc7-4331-ad1d-d0bebdb05d54","acronym":"","url":"https://clinicaltrials.gov/study/NCT01449461","created_at":"2021-01-17T17:28:43.410Z","updated_at":"2024-07-02T16:36:26.255Z","phase":"Phase 1/2","brief_title":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral Anaplastic Lymphoma Kinase (ALK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Brigatinib (AP26113)","source_id_and_acronym":"NCT01449461","lead_sponsor":"Ariad Pharmaceuticals","biomarkers":" ALK • ROS1","pipe":" | ","alterations":" EGFR mutation • EGFR T790M • ALK rearrangement • ROS1 fusion • ALK-ROS1 fusion","tags":["ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR T790M • ALK rearrangement • ROS1 fusion • ALK-ROS1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Alunbrig (brigatinib)"],"overall_status":"Completed","enrollment":" Enrollment 137","initiation":"Initiation: 09/20/2011","start_date":" 09/20/2011","primary_txt":" Primary completion: 11/16/2015","primary_completion_date":" 11/16/2015","study_txt":" Completion: 02/18/2020","study_completion_date":" 02/18/2020","last_update_posted":"2021-08-17"},{"id":"614858c2-6810-42e4-823a-d18ea5c881fa","acronym":"ALTA","url":"https://clinicaltrials.gov/study/NCT02094573","created_at":"2021-01-18T09:39:58.923Z","updated_at":"2024-07-02T16:36:33.308Z","phase":"Phase 2","brief_title":"A Study to Evaluate the Efficacy of Brigatinib (AP26113) in Participants With Anaplastic Lymphoma Kinase (ALK)-Positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib","source_id_and_acronym":"NCT02094573 - ALTA","lead_sponsor":"Ariad Pharmaceuticals","biomarkers":" ALK","pipe":" | ","alterations":" ALK positive • ALK rearrangement","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • Alunbrig (brigatinib)"],"overall_status":"Completed","enrollment":" Enrollment 222","initiation":"Initiation: 06/04/2014","start_date":" 06/04/2014","primary_txt":" Primary completion: 02/29/2016","primary_completion_date":" 02/29/2016","study_txt":" Completion: 02/27/2020","study_completion_date":" 02/27/2020","last_update_posted":"2021-03-15"},{"id":"e0c9f905-b9fe-4991-926f-025cb10a093b","acronym":"","url":"https://clinicaltrials.gov/study/NCT03719898","created_at":"2021-01-29T07:18:07.550Z","updated_at":"2024-07-02T16:36:36.578Z","phase":"Phase 2","brief_title":"Brigatinib in Relapsed or Refractory ALK-Positive Anaplastic Large Cell Lymphoma","source_id_and_acronym":"NCT03719898","lead_sponsor":"Fox Chase Cancer Center","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Alunbrig (brigatinib)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 12/06/2018","start_date":" 12/06/2018","primary_txt":" Primary completion: 03/18/2020","primary_completion_date":" 03/18/2020","study_txt":" Completion: 06/16/2020","study_completion_date":" 06/16/2020","last_update_posted":"2021-01-05"}]